This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Plasmapheresis and Immunosuppressive Drug Therapy in Myasthenia Gravis

List of authors.
  • Peter C. Dau, M.D.,
  • Jon M. Lindstrom, Ph.D.,
  • Christine K. Cassel, M.D.,
  • Eric H. Denys, M.D.,
  • Edward E. Shev, M.D.,
  • and Lynn E. Spitler, M.D.

Abstract

Plasmapheresis combined with prednisone and azathioprine therapy produced striking clinical improvement in five patients with myasthenia gravis who still had moderate to severe disability despite thymectomy, high-dose prednisone therapy and optimal doses of cholinesterase inhibitors. Serial determinations of titers of serum antibody toward the acetylcholine receptor demonstrated a fall to 21 ±5 per cent (mean ± S.D.) of the original levels concurrently with the patients' increasing strength. Clinically improved patients maintained lowered titers, whereas clinical relapses were associated with a rebound in titer.

Our results suggest that plasmapheresis will find a place in the management of patients with myasthenia gravis, and they implicate antibodies to acetylcholine receptor as a pathogenic factor in this disease. (N Engl J Med 297:1134–1140, 1977)

Funding and Disclosures

Supported by the Zimmerman Fund and the Muscular Dystrophy Association.

We are indebted to Drs. Calanchine, Clark, Novom and Vijayan for patient referral, and to Ms. Delila Baez, Barbara Nave and Charlotte Yano for assistance.

Author Affiliations

From the Muscular Dystrophy Association Neuromuscular Disease Center and the Paul M. Aggeler Memorial Laboratory, Children's Hospital of San Francisco, the Department of Medicine, School of Medicine, University of California, San Francisco, and the Salk Institute (address reprint requests to Dr. Dau at Children's Hospital of San Francisco, Paul M. Aggeler Memorial Laboratory, P.O. Box 3805, San Francisco, CA 94119).